113 related articles for article (PubMed ID: 2823435)
1. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation.
Saliba F; Gugenheim J; Samuel D; Bismuth A; Mathieu D; Serres C; Bismuth H
Transplant Proc; 1987 Oct; 19(5):4081-2. PubMed ID: 2823435
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment.
Dussaix E; Wood C
Transplantation; 1989 Aug; 48(2):272-4. PubMed ID: 2547257
[TBL] [Abstract][Full Text] [Related]
3. The role of CMV immune prophylaxis in patients at risk of primary CMV infection following orthotopic liver transplantation.
Bell R; Sheil AG; McDonald JA; McCaughan GW
Transplant Proc; 1989 Oct; 21(5):3781-2. PubMed ID: 2554546
[No Abstract] [Full Text] [Related]
4. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
5. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study.
Saliba F; Arulnaden JL; Gugenheim J; Serves C; Samuel D; Bismuth A; Mathieu D; Bismuth H
Transplant Proc; 1989 Feb; 21(1 Pt 2):2260-2. PubMed ID: 2540564
[No Abstract] [Full Text] [Related]
6. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
[No Abstract] [Full Text] [Related]
7. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
Snydman DR
Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
[No Abstract] [Full Text] [Related]
8. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
Condie RM; O'Reilly RJ
Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
[No Abstract] [Full Text] [Related]
9. Cost-effective use of cytomegalovirus immune globulin in recipients of orthotopic liver transplants.
Uber LA
Am J Hosp Pharm; 1994 Nov; 51(22):2843, 2846. PubMed ID: 7856614
[No Abstract] [Full Text] [Related]
10. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
[No Abstract] [Full Text] [Related]
11. Incidence of cytomegalovirus infection and its relationship to donor-recipient serologic status in liver transplantation.
Rakela J; Wiesner RH; Taswell HF; Hermans PE; Smith TF; Perkins JD; Krom RA
Transplant Proc; 1987 Feb; 19(1 Pt 3):2399-402. PubMed ID: 3029918
[No Abstract] [Full Text] [Related]
12. Cytomegalovirus prophylaxis after heart transplantation using specific hyperimmunoglobulin.
Schäfers HJ; Haverich A; Wahlers T; Milbradt H; Flik J; Fieguth HG; Borst HG
Transplant Proc; 1987 Oct; 19(5):4061-2. PubMed ID: 2823430
[No Abstract] [Full Text] [Related]
13. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
Bordigoni P; Janot C; Aymard JP; Witz F; Bené MC; Legras B; Schoonemann F; Olive D; Streiff F
Nouv Rev Fr Hematol (1978); 1987; 29(5):289-93. PubMed ID: 2830588
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464
[No Abstract] [Full Text] [Related]
15. CMV immunoglobulin for prevention of pneumonitis after BMT.
Klingemann HG; Phillips GL
Bone Marrow Transplant; 1988 May; 3(3):235-6. PubMed ID: 2844345
[No Abstract] [Full Text] [Related]
16. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins.
Chehimi J; Peppard J; Emanuel D
Bone Marrow Transplant; 1987 Dec; 2(4):395-402. PubMed ID: 2844341
[TBL] [Abstract][Full Text] [Related]
17. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir.
Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus and blood transfusion.
Tegtmeier GE
Prog Clin Biol Res; 1985; 182():175-99. PubMed ID: 2994097
[No Abstract] [Full Text] [Related]
20. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
